6-氯-3,4-联吡啶 | 79739-22-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-3,4-联吡啶
• 中文别名: 6-氯-3,4'-联吡啶
• 英文名称: 2-Chlor-5-(pyrid-4-yl)pyridin
• 英文别名: 6-chloro-3,4'-bipyridine；2-chloro-5-(4-pyridinyl)pyridine；2-chloro-5-pyridin-4-ylpyridine
• CAS: 79739-22-3
• 化学式: C₁₀H₇ClN₂
• mdl: MFCD00137926
• 分子量: 190.632
• InChiKey: AZESIBFJNSNUBT-UHFFFAOYSA-N

物化性质

• 熔点：
  160-162 °C(Solv: dichloromethane (75-09-2))
• 沸点：
  323.1±27.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-氯-3,4-联吡啶 在 palladium on activated charcoal 氢氧化钾 、 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以83%的产率得到3,4'-bipyridyl
  参考文献：
  名称：

  Shiao, Min-Jen; Shieh, Puh; Lai, Jen-Shiow, Synthetic Communications, 1988, vol. 18, # 12, p. 1397 - 1402

  摘要：

  DOI：
• 作为产物：
  描述：

  6'-methoxy-4,3'-bipyridine 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以72%的产率得到6-氯-3,4-联吡啶
  参考文献：
  名称：

  Shiao, Min-Jen; Shieh, Puh; Lai, Jen-Shiow, Synthetic Communications, 1988, vol. 18, # 12, p. 1397 - 1402

  摘要：

  DOI：

文献信息

• [EN] FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS<br/>[FR] COMPOSÉS CONDENSÉS DE PYRIDINE, DE PYRIMIDINE ET DE TRIAZINE EN TANT QU'INHIBITEURS DU CYCLE CELLULAIRE
  申请人：AMGEN INC

  公开号：WO2009085185A1

  公开（公告）日：2009-07-09

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.

  提供了一种化合物、药物组合物和方法，用于治疗CDK4介导的疾病，如癌症。所述化合物是融合的吡啶、嘧啶和三嗪衍生物。
• Compositions and their preparation
  申请人：Sterling Drug Inc.

  公开号：US04276293A1

  公开（公告）日：1981-06-30

  2-R.sub.2 -3-R.sub.3 -6-PY-5-Q-3H-imidazo[4,5-b]pyridines (I) or 1-R.sub.1 -2-R.sub.2 -6-PY-5-Q-1H-imidazo[4,5-b]pyridines (IA) or pharmaceutically-acceptable acid-addition salts thereof, where Q and R.sub.2 are each hydrogen or lower-alkyl, R.sub.1 and R.sub.3 are each hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages and NB is di-(lower-alkyl)amino or 4-morpholinyl, at least one of R.sub.1 or R.sub.3 being hydrogen, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, which are useful as cardiotonics, are prepared by reacting 2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-pyridine (II) with a tri-(lower-alkyl) ortho-(lower-alkanoate). Also shown are: the use of I or IA or salts in cardiotonic compositions and a method for increasing cardiac contractility; and, the preparation of the intermediates II, as well as intermediates used to prepare II.

  2-R.sub.2 -3-R.sub.3 -6-PY-5-Q-3H-咪唑并[4,5-b]吡啶（I）或1-R.sub.1 -2-R.sub.2 -6-PY-5-Q-1H-咪唑并[4,5-b]吡啶（IA）或其药用可接受的酸盐，其中Q和R.sub.2分别为氢或低烷基，R.sub.1和R.sub.3分别为氢、低烷基、低羟基烷基、2,3-二羟基丙基、低烷氧基烷基或Y-NB，其中Y为至少在其连接链之间具有两个碳原子的低烷基，NB为二（低烷基）氨基或4-吗啉基，R.sub.1或R.sub.3中至少一个为氢，PY为4-或3-吡啶基或带有一个或两个低烷基取代基的4-或3-吡啶基，这些化合物可用作心力衰竭药物，通过将2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-吡啶（II）与三（低烷基）邻-(低烷酸酯)反应制备。还显示了：在心力衰竭药物组合物中使用I或IA或盐以及增加心脏收缩力的方法；以及用于制备II的中间体II的制备，以及用于制备II的中间体。
• 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their
  申请人：Sterling Drug Inc.

  公开号：US04297360A1

  公开（公告）日：1981-10-27

  2-R.sub.3 RN-3-R.sub.1 R'N-5-PY-6-Q-pyridines (I) or pharmaceutically-acceptable acid-addition salts thereof are useful as intermediates in the preparation of 1- or 3-substituted-1,3-dihydro-5-Q-6-PY-2H-imidazo[4,5-b]pyridin-2-ones or -2-thiones and also as intermediates for preparing 1- or 3-substituted-5-Q-6-PY-3H(or 1H)-imidazo[4,5-b]pyridines, where R.sub.1, R.sub.3, R, R', PY and Q are defined hereinbelow. Also shown are processes for preparing I and the following intermediates used therein: 2-halo-3-nitro-5-PY-6-Q-pyridines (III), 2-R.sub.3 RN-3-nitro-5-PY-6-Q-pyridines (V), 2-halo-5-PY-6-Q-pyridines (VII), 2-R.sub.3 RN-5-PY-6-Q-pyridines (VIII) and 2-R.sub.3 RN-3-halo-5-PY-6-Q-pyridines (IX) or salts thereof. Certain embodiments of II and VIII also are useful as cardiotonics and are shown as active components of cardiac compositions and methods for increasing cardiac contractility.

  2-R.sub.3 RN-3-R.sub.1 R'N-5-PY-6-Q-吡啶类化合物（I）或其药用可接受的酸盐在制备1-或3-取代-1,3-二氢-5-Q-6-PY-2H-咪唑[4,5-b]吡啶-2-酮或-2-硫酮以及制备1-或3-取代-5-Q-6-PY-3H（或1H）-咪唑[4,5-b]吡啶的中间体中是有用的，其中R.sub.1、R.sub.3、R、R'、PY和Q的定义如下。还显示了制备I及其中使用的以下中间体的过程：2-卤代-3-硝基-5-PY-6-Q-吡啶类化合物（III）、2-R.sub.3 RN-3-硝基-5-PY-6-Q-吡啶类化合物（V）、2-卤代-5-PY-6-Q-吡啶类化合物（VII）、2-R.sub.3 RN-5-PY-6-Q-吡啶类化合物（VIII）和2-R.sub.3 RN-3-卤代-5-PY-6-Q-吡啶类化合物（IX）或其盐。II和VIII的某些实施例也可用作强心剂，并显示为心脏组合物的活性成分和增加心脏收缩力的方法。
• 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and
  申请人：Sterling Drug Inc.

  公开号：US04294837A1

  公开（公告）日：1981-10-13

  1,3-Dihydro-1-R.sub.1 -3-R.sub.3 -6-PY-5-Q-2H-imidazo[4,5-b]pyridin-2-ones or -2-thiones or pharmaceutically-acceptable acid-addition salts thereof, which are useful as cardiotonic agents, where Q is hydrogen or lower-alkyl, R.sub.1 and R.sub.3 are each hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene and NB is di-(lower-alkyl)amino or 4-morpholinyl, at least one of R.sub.1 and R.sub.3 being hydrogen, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two substituents, are prepared by reacting a 2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-pyridine with urea or carbonyldiimidazole to produce said -2-one or with an alkali metal xanthate, thiourea or thiocarbonyldiimidazole to produce said -2-thione. Also shown and claimed are cardiotonic compositions and a method for increasing cardiac contractility using said cardiotonic agents. Also shown are processes for preparing said intermediate 2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-pyridines and other intermediates used in said processes.

  1,3-二氢-1-R.sub.1-3-R.sub.3-6-PY-5-Q-2H-咪唑并[4,5-b]吡啶-2-酮或-2-硫酮或其药用可接受的酸加合物盐，可用作心力衰竭药物，其中Q为氢或较低烷基，R.sub.1和R.sub.3分别为氢、较低烷基、较低羟基烷基、2,3-二羟基丙基、较低烷氧基烷基或Y-NB，其中Y为较低烷基烯和NB为二-(较低烷基)氨基或4-吗啉基，R.sub.1和R.sub.3中至少有一个为氢，PY为4-或3-吡啶基或带有一个或两个取代基的4-或3-吡啶基，通过将2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-吡啶与尿素或羰基二咪唑反应制备所述的-2-酮，或与碱金属黄原酸酯、硫脲或硫代羰基二咪唑反应制备所述的-2-硫酮。还显示并声称心力衰竭组合物和使用所述心力衰竭药物增加心脏收缩力的方法。还显示了制备所述中间体2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-吡啶和所述过程中使用的其他中间体的方法。
• N-(Lower-alkyl)-N'-[5-(pyridinyl)-2-pyridinyl]ureas and cardiotonic use
  申请人：Sterling Drug Inc.

  公开号：US04448780A1

  公开（公告）日：1984-05-15

  N-R.sub.1 -N-(6-R-5-PY-2-pyridinyl)ureas, where R.sub.1 is lower-alkyl, R is hydrogen or lower-alkyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, or acid-addition salts thereof. Said compounds (I) or pharmaceutically acceptable acid-addition salts thereof are useful as cardiotonic agents. The preparation and cardiotonic use of said compounds are shown.

  N-R.sub.1-N-(6-R-5-PY-2-吡啶基)脲类化合物，其中R.sub.1是较低的烷基，R是氢或较低的烷基，PY是4-或3-吡啶基或带有一个或两个较低的烷基取代基的4-或3-吡啶基，或其酸盐。所述化合物(I)或其药用可接受的酸盐可用作强心剂。所述化合物的制备和强心用途已被证明。